Navigation Links
Munich researchers discover new target for tailored antibiotics
Date:7/14/2009

This release is available in German.

More and more strains of bacteria are developing resistance to previously life-saving antibiotics. Researchers at TUM, the Technische Universitaet Muenchen, have shed light on a metabolic step that appears in many aggressive microorganisms -- such as tuberculosis and malaria pathogens -- and that may provide a promising target for a new class of antibiotics. The researchers present their results in the chemistry journal Angewandte Chemie.

Antibiotics can hold harmful pathogens in check by interfering with their ability to produce essential compounds. Ever more bacterial strains are developing multiple antibiotic resistances, however, rendering previously life-saving medications ineffective. That is why researchers around the world are searching for new reaction steps that are vital to microorganisms but play no relevant role in humans. Professor Michael Groll, Dr. Jrg Eppinger, and Dr. Tobias Grwert, biochemists at the Technische Universitt Mnchen, and their research team have described in detail the structural basis for just such a reaction step.

The cells of virtually all life forms synthesize essential natural substances belonging to the class of terpenes and steroids from the small isoprene building blocks dimethylallyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP). Mammals and a large number of other organisms generate these essential metabolites via the so-called mevalonate pathway. But most human pathogens, including Plasmodium falciparum, have developed an alternate mechanism for producing these important substances. Now, this special pathway may spell doom for those bacteria. The TUM researchers have unraveled the structural basis of the terminal step in bacterial isoprene synthesis. The crucial enzyme has a most unusual structure, similar to a three-leaf clover, and may open a potent line of attack for custom-tailored antibiotics.

Research into the bacterial synthesis of isoprene building blocks was initiated as early as 12 years ago by Professor Adelbert Bacher in collaboration with Drs. Wolfgang Eisenreich and Felix Rohdich in Organic Chemistry and Biochemistry. Over the years, the team discovered most of the reaction steps of the new metabolic pathway. Yet the structure of the terminal step catalyzed by the IspH enzyme remained stubbornly elusive. Earlier measurements suggested that the active core must be an iron-sulfur cluster with three iron and four sulfur atoms. But other researchers questioned the results, and for many years the crystal structure of the enzyme that would provide the proof could not be determined.

The main problem was the oxygen sensitivity of the enzyme, which degenerates very quickly in air, thus losing both its structure and its function. Only recently a group from the Justus-Liebig University in Giessen managed to determine the X-ray crystal structure of the enzyme's open state. However, this structure provides hardly any information on the mutation process catalyzed by the enzyme. The research team of Professor Groll, Dr. Eppinger, and Dr. Grwert has now succeeded in cracking the closed-state X-ray structure that shows the precise folding pattern of the protein chain and the chemical environment of the active site cavity.

The crystal structure opened the door to a detailed examination of the reaction mechanism using computer simulation and mutagen experiments, in which E. coli bacteria are coerced into synthesizing defective IspH enzymes. Thus, the X-ray structure, kinetic measurements, and mutagenic analyses ultimately confirmed the unusual arrangement of three iron and four sulfur atoms in the central cavity, just as proposed years ago.

"Now that the location, the chemical process, and the helpers involved in the IspH reaction have been identified," explains Groll, "we have a new angle of attack for developing substances that block the terminal step in the bacterial synthesis of isoprene building blocks, thereby killing pathogens in a very targeted way. Since the enzyme and the associated reaction do not appear in mammals, these compounds should have few or no side effects in humans."


'/>"/>

Contact: Dr. Andreas Battenberg
battenberg@zv.tum.de
49-892-891-2890
Technische Universitaet Muenchen
Source:Eurekalert

Related biology news :

1. Munich researchers discover key allergy gene
2. 2 Alexander von Humboldt professorships go to LMU Munich
3. Researchers identify proteins involved in new neurodegenerative syndrome
4. Texas researchers and educators head for Antarctica
5. MGH researchers describe new way to identify, evolve novel enzymes
6. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
7. U of MN researchers discover noninvasive diagnostic tool for brain diseases
8. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
9. Researchers discover new strategies for antibiotic resistance
10. Researchers find new taste in fruit flies: carbonated water
11. Binghamton University researchers investigate evolving malaria resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology: